PMID- 38087497
OWN - NLM
STAT- MEDLINE
DCOM- 20240221
LR  - 20240221
IS  - 1747-6356 (Electronic)
IS  - 1747-6348 (Linking)
VI  - 17
IP  - 12
DP  - 2023 Dec
TI  - High risks adverse events associated with usage of aspirin in chronic obstructive 
      pulmonary disease.
PG  - 1285-1295
LID - 10.1080/17476348.2023.2294927 [doi]
AB  - BACKGROUND: Despite potential benefits and widespread prescription of aspirin 
      among chronic obstructive pulmonary disease (COPD) patients, limited research has 
      investigated its adverse effects (AEs) in COPD population. METHODS: We conducted 
      a retrospective analysis of adverse drug events (ADEs) reported in the US Food 
      and Drug Administration Adverse Event Reporting System (FAERS) between Q1 2013 
      and Q2 2022. COPD patients were categorized into two groups based on aspirin use. 
      ADEs related to aspirin use were identified using combined reporting odds ratio 
      (ROR), proportional reporting ratio (PRR), information component (IC) methods. 
      RESULTS: A total of 56,660 ADEs reports associated with COPD patients were 
      included in the study. Among these reports, 144 adverse events were linked to 
      aspirin use in COPD patients, including fatigue (4.12%), diarrhea (3.13%), 
      dyspnea exertional (2.03%), rhinorrhea (1.99%), weight increased (1.89%) and 
      vomiting (1.84%), muscle spasms (1.79%), cardiac disorder (1.74%), heart rate 
      increased (1.69%) and peripheral swelling (1.59%). Subgroup analysis indicates 
      that age and gender might affect the AEs frequency in COPD patients using 
      aspirin. CONCLUSIONS: Our findings identify 10 most frequently reported ADEs 
      associated with aspirin use in COPD patients, thus offer valuable insights into 
      the AEs of aspirin for safer clinical utilization in COPD management.
FAU - Li, Xiaohua
AU  - Li X
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
AD  - Department of Respiratory and Critical Care Medicine, Sixth People's Hospital of 
      Chengdu, Chengdu, Sichuan, China.
FAU - Dai, Bin
AU  - Dai B
AD  - Department of Respiratory and Critical Care Medicine, The General Hospital of 
      Western Theatre Command, Chengdu, Sichuan, China.
FAU - Han, Qingbing
AU  - Han Q
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
FAU - Wu, Yanqiu
AU  - Wu Y
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
FAU - Ran, Bi
AU  - Ran B
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
FAU - Wen, Fuqiang
AU  - Wen F
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Respiratory and Critical Care Medicine, West China Hospital, West 
      China School of Medicine, and Division of Pulmonary Diseases, State Key 
      Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20231219
PL  - England
TA  - Expert Rev Respir Med
JT  - Expert review of respiratory medicine
JID - 101278196
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Humans
MH  - Aspirin/adverse effects
MH  - Adverse Drug Reaction Reporting Systems
MH  - Retrospective Studies
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology
OTO - NOTNLM
OT  - Aspirin
OT  - COPD treatment
OT  - FAERS database
OT  - adverse drug events
OT  - safe clinical utilization
EDAT- 2023/12/13 06:42
MHDA- 2024/02/21 11:16
CRDT- 2023/12/13 00:52
PHST- 2024/02/21 11:16 [medline]
PHST- 2023/12/13 06:42 [pubmed]
PHST- 2023/12/13 00:52 [entrez]
AID - 10.1080/17476348.2023.2294927 [doi]
PST - ppublish
SO  - Expert Rev Respir Med. 2023 Dec;17(12):1285-1295. doi: 
      10.1080/17476348.2023.2294927. Epub 2023 Dec 19.